Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop

Multiple Sclerosis Journal

Volumn 24, Issue 5, 2018, Pages 590-603

  Amato, Maria Pia ^a   Derfuss, Tobias ^b   Hemmer, Bernard ^c   Liblau, Roland ^d   Montalban, Xavier ^e   Sørensen, Per Soelberg ^f   Miller, David H ^g  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e EUI   (Spain)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

comorbidities; environmental risk factors; infections; lifestyle; Multiple sclerosis; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BCG VACCINE; BETA1A INTERFERON; COLECALCIFEROL; EPSTEIN BARR VIRUS VACCINE; GLATIRAMER; HLA DRB1 ANTIGEN; HLA DRB5 ANTIGEN; INTERFERON BETA SERINE; NUCLEOSIDE ANALOG; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RALTEGRAVIR; RITUXIMAB;

ADD ON THERAPY; ALCOHOL CONSUMPTION; BODY MASS; CIGARETTE SMOKING; COFFEE; COMORBIDITY; CONFERENCE PAPER; CYTOKINE RELEASE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE COMPARISON; ENDOGENOUS RETROVIRUS; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS INFECTION; EXPANDED DISABILITY STATUS SCALE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYGIENE HYPOTHESIS; INTESTINE FLORA; MENTAL STRESS; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SALT INTAKE; THERAPY WITH HELMINTHS; TRICHURIS SUIS; VITAMIN D DEFICIENCY;

EID: 85029620990     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516686847     Document Type: Article

References (89)

1. Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol 2015; 14: 406–419.
2. Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin 2016; 34: 919–939.
3. Kalincik T, Bulzkueven H. Observational data: Understanding the real MS world. Mult Scler 2016; 22: 1642–1648.
4. Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis – A quiet revolution. Nat Rev Neurol 2015; 11: 134–142.
5. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3: 104–110.
6. Sawcer S, Hellenthal G, Pirinen M.; International Multiple Sclerosis Genetics Consortium and Wellcome Trust Case Control Consortium. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.
7. Beecham AH, Patsopoulos NA, Xifara DK.; International Multiple Sclerosis Genetics Consortium. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45: 1353–1360.
8. Ramagopalan SV, Ebers GC. Multiple sclerosis: Major histocompatibility complexity and antigen presentation. Genome Med 2009; 1: gm105.
9. McKay KA, Jahanfar S, Duggan T. Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. Neurotoxicology. Epub ahead of print 1 April 2016. DOI: 10.1016/j.neuro.2016.03.020.
10. Hillert J, Stawiarz L. The Swedish MS registry – Clinical support tool and scientific resource. Acta Neurol Scand 2015; 132: 11–19.
11. Ramagopalan SV, Dobson R, Meier UC. Multiple sclerosis: Risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9: 727–739.
12. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 4: 195–202.
13. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol 2007; 61: 288–299.
14. Ascherio A, Munger KL, Lünemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012; 5: 602–612.
15. Goulden R, Ibrahim T, Wolfson C. Is high socioeconomic status a risk factor for multiple sclerosis? A systematic review. Eur J Neurol 2015; 22: 899–911.
16. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: A meta-analysis. Ann Neurol 2006; 59: 499–503.
17. Levin LI, Munger KL, O’Reilly EJ. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67: 824–830.
18. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol 1995; 47: 425–448.
19. Smith C, Khanna R. The development of prophylactic and therapeutic EBV vaccines. Curr Top Microbiol Immunol 2015; 391: 455–473.
20. Gasperi C, Stüve O, Hemmer B. B cell-directed therapies in multiple sclerosis. Neurodegener Dis Manag 2016; 6: 37–47.
21. Dreyfus DH. Autoimmune disease: A role for new anti-viral therapies? Autoimmun Rev 2011; 11: 88–97.
22. Marta M, MacManus D, Yousry T. Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: The INSPIRE study results. Mult Scler 2016; 22(Suppl. 3): 188.
23. Ristori G, Romano S, Cannoni S. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology 2014; 82: 41–48.
24. Correale J, Farez MF. The impact of environmental infections (parasites) on MS activity. Mult Scler 2011; 17: 1162–1169.
25. Voldsgaard A, Bager P, Garde E. Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Mult Scler 2015; 21: 1723–1729.
26. Smolders J, Damoiseaux J. Vitamin D as a T-cell modulator in multiple sclerosis. Vitam Horm 2011; 86: 401–428.
27. Wergeland S, Torkildsen Ø, Myhr KM. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLoS ONE 2011; 6: e26262.
28. Niino M, Miyazaki Y. Genetic polymorphisms related to vitamin D and the therapeutic potential of vitamin D in multiple sclerosis. Can J Physiol Pharmacol 2015; 93: 319–325.
29. Munger KL, Åivo J, Hongell K. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish Maternity Cohort. JAMA Neurol 2016; 73: 515–519.
30. Mokry LE, Ross S, Ahmed OS. Vitamin D and risk of multiple sclerosis: A Mendelian randomization study. PLoS Med 2015; 12: e1001866.
31. Rhead B, Bäärnhielm M, Gianfrancesco M. Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet 2016; 2: e97.
32. Burton JM, Kimball S, Vieth R. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852–1859.
33. Kimball S, Vieth R, Dosch HM. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab 2011; 96: 2826–2834.
34. Soilu-Hänninen M, Aivo J, Lindström BM. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 565–571.
35. Kampman MT, Steffensen LH, Mellgren SI. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: Exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012; 18: 1144–1151.
36. Stein MS, Liu Y, Gray OM. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011; 77: 1611–1618.
37. Mosayebi G, Ghazavi A, Ghazami K. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 2011; 40: 627–639.
38. Smolders J, Hupperts R, Barkhof F. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2001; 311: 44–49.
39. Bhargava P, Cassard S, Steele SU. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials 2014; 39: 288–293.
40. Dörr J, Ohiraun S, Skarabis H. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): Study protocol for a randomized controlled trial. Trials 2012; 13: 15.
41. MS Research Australia. Vitamin D MS prevention trial: Update 22 June 2016, http://www.msra.org.au/vitamin-d-ms-prevention-trial-update (accessed 29 July 2016).
42. Ascherio A, Munger KL, White R. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71: 306–314.
43. Fitzgerald KC, Munger KL, Köchert K. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol 2015; 72: 1458–1465.
44. Handel AE, Williamson AJ, Disanto G. Smoking and multiple sclerosis: An updated meta-analysis. PLos ONE 2011; 6: e16149.
45. Hedström AK, Hillert J, Olsson T. Smoking and multiple sclerosis susceptibility. Eur J Epidemiol 2013; 28: 767–774.
46. Salzer J, Hallmans G, Nyström M. Smoking as a risk factor for multiple sclerosis. Mult Scler 2013; 19: 1022–1027.
47. Palacios N, Alonso A, Brønnum-Hansen H. Smoking and increased risk of multiple sclerosis: Parallel trends in the sex ratio reinforce the evidence. Ann Epidemiol 2011; 21: 536–542.
48. Di Pauli F, Reindl M, Ehling R. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008; 14: 1026–1030.
49. Manouchehrinia A, Tench CR, Maxted J. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain 2013; 136: 2298–2304.
50. Ramanujam R, Hedström AK, Manouchehrinia A. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol 2015; 72: 1117–1123.
51. Barragán-Martinez C, Speck-Hernández CA, Montoya-Ortiz G. Organic solvents as risk factor for autoimmune diseases: A systematic review and meta-analysis. PLoS ONE 2012; 7: e51506.
52. Hedström AK, Bäärnhielm M, Olsson T. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009; 73: 696–701.
53. Odoardi F, Sie C, Streyl K. T cells become licensed in the lung to enter the central nervous system. Nature 2012; 488: 675–679.
54. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology 2009; 73: 1543–1550.
55. Wesnes K, Riise T, Casetta I. Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. Mult Scler 2015; 21: 388–395.
56. Gianfrancesco MA, Acuna B, Shen L. Obesity during childhood and adolescence increases susceptibility to multiple sclerosis after accounting for established genetic and environmental risk factors. Obes Res Clin Pract 2014; 8: e435–e447.
57. Hedström AK, Olsson T, Alfredsson L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012; 18: 1334–1336.
58. Hedström AK, Lima Bomfim I, Barcellos L. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 2014; 82: 865–872.
59. Ponsonby AL, Lucas RM, Dear K. The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study. Mult Scler 2013; 19: 1717–1725.
60. Munger KL, Bentzen J, Laursen B. Childhood body mass index and multiple sclerosis risk: A long-term cohort study. Mult Scler 2013; 19: 1323–1329.
61. Langer-Gould A, Brara SM, Beaber BE. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013; 80: 548–552.
62. Matarese G, Carrieri PB, La Cava A. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2005; 102: 5150–5155.
63. Matarese G, Di Giacomo A, Sanna V. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 2001; 166: 5909–5918.
64. Kvistad SS, Myhr KM, Holmøy T. Body mass index influence interferon-beta treatment response in multiple sclerosis. J Neuroimmunol 2015; 288: 92–97.
65. Kappus N, Weinstock-Guttman B, Hagemeier J. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 181–187.
66. Tettey P, Siejka D, Simpson S, Jr. Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis. Neuroepidemiology 2016; 46: 106–113.
67. Marrie RA, Horwitz R, Cutter G. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009; 72: 117–124.
68. Hucke S, Wiendl H, Klotz L. Implications of dietary salt intake for multiple sclerosis pathogenesis. Mult Scler 2016; 22: 133–139.
69. Hedström AK, Hillert J, Olsson T. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurol 2014; 71: 300–305.
70. Wang T, Xi NN, Chen Y. Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: Therapeutic window and receptor subtype mechanism. Neuropharmacology 2014; 86: 203–211.
71. Hedström AK, Mowry EM, Gianfrancesco MA. High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies. J Neurol Neurosurg Psychiatry 2016; 87: 454–460.
72. Massa J, O’Reilly EJ, Munger KL. Caffeine and alcohol intakes have no association with risk of multiple sclerosis. Mult Scler 2013; 19: 53–58.
73. Li J, Johansen C, Brønnum-Hansen H. The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark. Neurology 2004; 62: 726–729.
74. Nielsen NM, Bager P, Simonsen J. Major stressful life events in adulthood and risk of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 1103–1108.
75. Nielsen NM, Pedersen BV, Stenager E. Stressful life-events in childhood and risk of multiple sclerosis: A Danish nationwide cohort study. Mult Scler 2014; 20: 1609–1615.
76. Golan D, Somer E, Dishon S. Impact of exposure to war stress on exacerbations of multiple sclerosis. Ann Neurol 2008; 64: 143–148.
77. Mohr DC, Hart SL, Julian L. Association between stressful life events and exacerbation in multiple sclerosis: A meta-analysis. BMJ 2004; 328: 731.
78. Gold SM, Mohr DC, Huitinga I. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol 2005; 26: 644–652.
79. Zhang T, Tremlett H, Leung S. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology 2016; 86: 1287–1295.
80. Berrigan LI, Fisk JD, Patten SB. Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity. Neurology 2016; 86: 1417–1424.
81. Berer K, Mues M, Koutrolos M. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479: 538–541.
82. Lee YK, Menezes JS, Umesaki Y. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2011; 108(Suppl. 1): 4615–4622.
83. Jangi S, Gandhi R, Cox LM. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun 2016; 7: 12015.
84. Chen J, Chia N, Kalari KR. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep 2016; 6: 28484.
85. Tremlett H, Fadrosh DW, Faruqi AA. Gut microbiota composition and relapse risk in pediatric MS: A pilot study. J Neurol Sci 2016; 363: 153–157.
86. Ascherio A, Munger KL. Epidemiology of multiple sclerosis: From risk factors to prevention – An update. Semin Neurol 2016; 36: 103–114.
87. Van der Mei I, Lucas RM, Yaylor BV. Population attributable fractions and joint effects of key risk factors for multiple sclerosis. Mult Scler 2016; 22: 461–469.
88. De Jager PL, Chibnik LB, Cui J. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: A weighted genetic risk score. Lancet Neurol 2009; 8: 1111–1119.
89. Petersen ER, Oturai AB, Koch-Henriksen N. Effect of smoking, a NAT1 genetic variant and HLA genes on disease activity in MS patients before and during interferon-beta treatment. Mult Scler 2016; 22(Suppl. 3): 58.